Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization.

Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a vaccine formulation. PBs can contain high concentrations of antigen, are stable and relatively resistant to proteases, release antigen slowly and are cost-effective to manufacture. Yet, the capacity of PBs to provoke immune responses and protection in the upper respiratory tract, a major entry route of respiratory pathogens, is largely unknown. In this study, we vaccinated mice intranasally with PBs comprising antigens from Streptococcus pneumoniae and evaluated the level of protection against nasopharyngeal colonization. PBs composed of the α-helical domain of pneumococcal surface protein A (PspAα) provided superior protection against colonization with S. pneumoniae compared to soluble PspAα. Immunization with soluble protein or PBs induced differences in antibody binding to pneumococci as well as a highly distinct antigen-specific nasal cytokine profile upon in vivo stimulation with inactivated S. pneumoniae. Moreover, immunization with PBs composed of conserved putative pneumococcal antigens reduced colonization by S. pneumoniae in mice, both as a single- and as a multi-antigen formulation. In conclusion, PBs represent a vaccine formulation that elicits strong mucosal immune responses and protection. The versatility of this platform offers opportunities for development of next-generation vaccine formulations. Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Citation

L F van Beek, J D Langereis, H B van den Berg van Saparoea, J Gillard, W S P Jong, F J van Opzeeland, R Mesman, L van Niftrik, I Joosten, D A Diavatopoulos, J Luirink, M I de Jonge. Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization. Vaccine. 2021 Nov 16;39(47):6920-6929

Mesh Tags

Substances

PMID: 34696934

search → result